About Pricing FAQs Providers Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDPhase 2/3NCT01460706

Imaging Malignant Glioma With 68Ga-DOTATOC PET/CT

The purpose of this study is to characterize tumour uptake of somatostatin analog 68Ga-DOTATOC in patients with either primary or recurrent malignant glioma. The investigators hypothesis is that some ...

Lead sponsor: Turku University Hospital•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Turku University Hospital

Age

18 - 70 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Age: 18 to 70 years old
•Language spoken: Finnish or Swedish
•Performance status: Karnofsky score 70 or better or WHO performance status 2 or better
•Supratentorial malignant glioma based on MRI imaging
•Supratentorial recurrent glioma based on MRI and/or \[11C\]methionine PET imaging
•Patients must be able to understand the meaning of the study and sign the appropriate Ethical Committee approved informed consent documents in the presence of the designated staff

Exclusion Criteria

•Any medical or psychiatric condition that compromises the subject´s ability to participate in the study
•Any other significant disease including liver or renal disease
•Pregnant or lactating women

Related studies

RECRUITINGPhase 3

A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma

NCT04166409 · Low Grade Astrocytoma, Low Grade Glioma, and more

RECRUITINGEARLY Phase 1

Window-of-Opportunity Trial of Ulixertinib for MAPK-Activated Gliomas

NCT05804227 · Gliomas

RECRUITINGPhase 1

A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma

NCT07464925 · Glioblastoma Multiforme of Brain, Glioma, and more

Symptom Cluster Heterogeneity and Gut Microbiota Mechanisms in Childhood Cancer Survivors

NCT07450872 · Cancer, Glioma, and more

Three miRNA Signatures in Glioma: From Molecular Mechanisms to Potential Clinical Application

NCT06883214 · Glioma

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: December 12, 2013Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE2/PHASE3

Enrollment30

Start dateOct 2011

Last updatedDec 12, 2013

Condition

Locations shown

Turku PET Centre, Turku University Hospital

Turku

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 12, 2013Data synced to Clareo: July 13, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions